| Nov 4 |
Glaukos Non-GAAP EPS of -$0.28 beats by $0.20, revenue of $96.67M beats by $5.2M
|
| Nov 4 |
Glaukos: Q3 Earnings Snapshot
|
| Nov 4 |
Glaukos Announces Third Quarter 2024 Financial Results
|
| Nov 3 |
Glaukos Q3 2024 Earnings Preview
|
| Oct 29 |
Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth
|
| Oct 28 |
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
| Oct 17 |
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
|
| Oct 17 |
Glaukos eyes FDA approval for ocular therapy after Phase III win
|
| Oct 16 |
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
|
| Oct 14 |
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
|
